147. Siu YP, Tong MK, Leung K et al. The use of enteric-coated
mycophenolate sodium in the treatment of relapsing and steroid-
dependent minimal change disease. J Nephrol 2008; 21: 127–131.
148. Jennette JC, Falk RJ. Adult minimal change glomerulopathy with acute
renal failure. Am J Kidney Dis 1990; 16: 432–437.
149. Lechner BL, Bockenhauer D, Iragorri S et al. The risk of cardiovascular
disease in adults who have had childhood nephrotic syndrome.
Pediatr Nephrol 2004; 19: 744–748.
150. Yalavarthy R, Smith ML, Edelstein C. Acute kidney injury complicating
minimal change disease: the case for careful use of diuretics and
angiotensin-converting enzyme inhibitors. Nephrology (Carlton) 2007;
12: 529–531.
151. Colquitt JL, Kirby J, Green C et al. The clinical effectiveness and cost-
effectiveness of treatments for children with idiopathic steroid-resistant
nephrotic syndrome: a systematic review. Health Technol Assess 2007;
11: iii–iiv, ix–xi, 1–93.
152. D’Agati V. Pathologic classification of focal segmental glomerulo-
sclerosis. Semin Nephrol 2003; 23: 117–134.
153. Braden GL, Mulhern JG, O’Shea MH et al. Changing incidence of
glomerular diseases in adults. Am J Kidney Dis 2000; 35: 878–883.
154. Haas M, Meehan SM, Karrison TG et al. Changing etiologies of
unexplained adult nephrotic syndrome: a comparison of renal biopsy
findings from 1976 to 1979 and 1995 to 1997. Am J Kidney Dis 1997; 30:
621–631.
155. Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and
treatment of focal segmental glomerulosclerosis. Neth J Med 2008; 66:
3–12.
156. Deegens JK, Dijkman HB, Borm GF et al. Podocyte foot process
effacement as a diagnostic tool in focal segmental glomerulosclerosis.
Kidney Int 2008; 74: 1568–1576.
157. Aucella F, De Bonis P, Gatta G et al. Molecular analysis of NPHS2 and
ACTN4 genes in a series of 33 Italian patients affected by adult-onset
nonfamilial focal segmental glomerulosclerosis. Nephron Clin Pract 2005;
99: c31–c36.
158. Caridi G, Bertelli R, Scolari F et al. Podocin mutations in sporadic focal-
segmental glomerulosclerosis occurring in adulthood. Kidney Int 2003;
64: 365.
159. Gigante M, Pontrelli P, Montemurno E et al. CD2AP mutations are
associated with sporadic nephrotic syndrome and focal segmental
glomerulosclerosis (FSGS). Nephrol Dial Transplant 2009; 24:
1858–1864.
160. He N, Zahirieh A, Mei Y et al. Recessive
NPHS2 (Podocin) mutations
are rare in adult-onset idiopathic focal segmental glomerulosclerosis.
Clin J Am Soc Nephrol 2007; 2: 31–37.
161. Machuca E, Hummel A, Nevo F et al. Clinical and epidemiological
assessment of steroid-resistant neph rotic syndrome associated with the
NPHS2 R229Q variant. Kidney Int 2009; 75: 727–735.
162. Santin S, Ars E, Rossetti S et al. TRPC6 mutational analysis in a large
cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial
Transplant 2009; 24: 3089–3096.
163. Santin S, Garcia-Maset R, Ruiz P et al. Nephrin mutations cause
childhood- and adult-onset focal segmental glomerulosclerosis. Kidney
Int 2009; 76: 1268–1276.
164. Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic
ApoL1 variants with kidney disease in African Americans. Science 2010;
329: 841–845.
165. Cameron JS, Turner DR, Ogg CS et al. The long-term prognosis of
patients with focal segmental glomerulosclerosis. Clin Nephrol 1978; 10:
213–218.
166. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental
glomerulosclerosis: clinical course and response to therapy. Am J Kidney
Dis 1994; 23: 773–783.
167. Velosa JA, Donadio Jr JV, Holley KE. Focal sclerosing glomerulonephro-
pathy: a clinicopathologic study. Mayo Clin Proc 1975; 50: 121–133.
168. Banfi G, Moriggi M, Sabadini E et al. The impact of prolonged
immunosuppression on the outcome of idiopathic focal-segmental
glomerulosclerosis with nephrotic syndrome in adults. A collaborative
retrospective study. Clin Nephrol 1991; 36: 53–59.
169. Cattran DC, Rao P. Long-term outcome in children and adults with
classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32:
72–79.
170. Korbet SM. Treatment of primary focal segmental glomerulosclerosis.
Kidney Int 2002; 62: 2301–2310.
171. Rydel JJ, Korbet SM, Borok RZ et al. Focal segmental glomerular sclerosis
in adults: presenta tion, course, and response to treatment. Am J Kidney
Dis 1995; 25: 534–542.
172. Goumenos DS, Tsagalis G, El Nahas AM et al. Immunosuppressive
treatment of idiopathic focal segmental glomerulosclerosis: a five-year
follow-up study. Nephron Clin Pract 2006; 104: c75–c82.
173. Pei Y, Cattran D, Delmore T et
al. Evidence suggesting under-treatment
in adults with idiopathic focal segmental glomerulosclerosis. Regional
Glomerulonephritis Registry Study. Am J Med 1987; 82: 938–944.
174. Stirling CM, Mathieson P, Boulton-Jones JM et al. Treatment and
outcome of adult patients with primary focal segmental
glomerulosclerosis in five UK renal units. QJM 2005; 98: 443–449.
175. Wehrmann M, Bohle A, Held H et al. Long-term prognosis of focal
sclerosing glomerulonephritis. An analysis of 250 cases with particular
regard to tubulointerstitial changes. Clin Nephrol 1990; 33: 115–122.
176. Caridi G, Gigante M, Ravani P et al. Clinical features and long-term
outcome of nephrotic syndrome associated with heterozygous NPHS1
and NPHS2 mutations. Clin J Am Soc Nephrol 2009; 4: 1065–1072.
177. Beaufils H, Alphonse JC, Guedon J et al. Focal glomerulosclerosis: natural
history and treatment. A report of 70 cases. Nephron 1978; 21: 75–85.
178. Praga M, Martinez MA, Andres A et al. Acute renal failure and tubular
dysfunction associated with minimal change nephrotic syndrome.
Nephrol Dial Transplant 1989; 4: 914–916.
179. Deegens JK, Assmann KJ, Steenbergen EJ et al. Idiopathic focal
segmental glomerulosclerosis: a favourable prognosis in untreated
patients? Neth J Med 2005; 63: 393–398.
180. Gupta K, Iskandar SS, Daeihagh P et al. Distribution of pathologic
findings in individuals with nephrotic proteinuria according to serum
albumin. Nephrol Dial Transplant 2008; 23: 1595–1599.
181. Duncan N, Dhaygude A, Owen J et al. Treatment of focal and segmental
glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial
Transplant 2004; 19: 3062–3067.
182. Cattran DC, Alexopoulos E, Heering P et al. Cyclosporin in idiopathic
glomerular disease associated with the nephrotic syndrome : workshop
recommendations. Kidney Int 2007; 72: 1429–1447.
183. Shiiki H, Nishino T, Uyama H et al. Clinical and morphological predictors
of renal outcome in adult patients with focal and segmental
glomerulosclerosis (FSGS). Clin Nephrol 1996; 46: 362–368.
184. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for
focal segmental glomerulosclerosis in adults. Cochrane Database of
Systematic Reviews 2008: CD003233.
185. Cattran DC, Appel GB, Hebert LA et al. A
randomized trial of
cyclosporine in patients with steroid-resistant focal segmental
glomerulosclerosis. North America Nephrotic Syndrome Study Group.
Kidney Int 1999; 56: 2220–2226.
186. Ghiggeri GM, Catarsi P, Scolari F et al. Cyclosporine in patients with
steroid-resistant nephrotic syndrome: an open-label, nonrandomized,
retrospective study. Clin Ther 2004; 26: 1411–1418.
187. Heering P, Braun N, Mullejans R et al. Cyclosporine A and chlorambucil
in the treatment of idiopathic focal segmental glomerulosclerosis.
Am J Kidney Dis 2004; 43: 10–18.
188. Ittel TH, Clasen W, Fuhs M et al. Long-term ciclosporine A treatment in
adults with minimal change nephrotic syndrome or focal segmental
glomerulosclerosis. Clin Nephrol 1995; 44: 156–162.
189. Melocoton TL, Kamil ES, Cohen AH et al. Long-term cyclosporine A
treatment of steroid-resistant and steroid-dependent nephrotic
syndrome. Am J Kidney Dis 1991; 18: 583–588.
190. Segarra A, Vila J, Pou L et al. Combined therapy of tacrolimus and
corticosteroids in cyclosporin-resistant or -dependent idiopathic focal
glomerulosclerosis: a preliminary uncontrolled study with prospective
follow-up. Nephrol Dial Transplant 2002; 17: 655–662.
191. Abe S, Amagasaki Y, Konishi K et al. Idiopathic membranous
glomerulonephritis: aspects of geographical differences. J Clin Pathol
1986; 39: 1193–1198.
192. Cahen R, Francois B, Trolliet P et al. Aetiology of membranous
glomerulonephritis: a prospective study of 82 adult patients. Nephrol
Dial Transplant 1989; 4: 172–180.
193. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson
JL, Schwartz MM (eds). Heptinstall’s Pathology of the Kidney, 6th edn,
vol. 1. Lippincott Williams & Wilkins: Philadelphia, PA, 2007, pp 205–251.
194. Kuroki A , Shibata T, Honda H et al. Glomerular and serum IgG subclasses
in diffuse proliferative lupus nephritis, membranous lupus nephritis, and
idiopathic membranous nephropathy. Intern Med 2002; 41: 936–942.
195. Ohtani H, Wakui H, Komatsuda A et al. Distribution of glomerular IgG
subclass deposits in malignancy-associated membranous nephropathy.
Nephrol Dial Transplant 2004; 19: 574–579.
196. Zeng CH, Chen HM, Wang RS et al. Etiology and clinical characteristics of
membranous nephropathy in Chinese patients. Am J Kidney Dis 2008;
52: 691–698.
262 Kidney International Supplements (2012) 2, 259–274
references